

In re of Appln. No. 09/441,140

amyloid monoclonal antibody [with heparan-like characteristics]. In a further preferred embodiment, the expression vector includes the sequence for the single chain monoclonal antibody of the above anti- $\beta$ -amyloid mAb.

In the ABSTRACT, please amend as follows:

A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and are non-inhibitory to the biological activity of the target molecule. The method [molecules denaturing] involves denaturing a target molecule in the presence of [presumptative] presumptive antiaggregation molecules to prevent the target molecules from self-or induced-aggregation. The nonaggregated target molecule coupled to the anti-aggregation molecule is then tested for bioactivity.

#### IN THE CLAIMS

Please cancel Claims 126-149 without prejudice to the continuation of prosecution thereof in a divisional application.

Please insert new claims 150-167 as follows:

150. A pharmaceutical formulation, comprising:

(A) an antibody or antigen binding fragment thereof,

wherein:

(i) said antibody and said fragment recognize an epitope within residues 1-28 of beta-amyloid, and